These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 31164885)

  • 1. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
    Geller A; Yan J
    Front Immunol; 2019; 10():1074. PubMed ID: 31164885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune evasion of tumor cells using membrane-bound complement regulatory proteins.
    Gorter A; Meri S
    Immunol Today; 1999 Dec; 20(12):576-82. PubMed ID: 10562709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.
    Kesselring R; Thiel A; Pries R; Fichtner-Feigl S; Brunner S; Seidel P; Bruchhage KL; Wollenberg B
    Eur J Cancer; 2014 Aug; 50(12):2152-61. PubMed ID: 24915776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of membrane complement regulatory proteins in cancer immunotherapy.
    Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
    Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
    Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
    Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
    Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
    Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
    Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
    Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
    Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of membrane-bound complement regulatory proteins suppresses colon cancer growth in mice through inducing tumor cell apoptosis.
    Tang G; Pan L; Wang Z; Zhu H; Yang Y; Wang Z; Yue H; Shi Y; Wu D; Jiang Z; Jiang D
    Int Immunopharmacol; 2023 Jan; 114():109450. PubMed ID: 36446233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer.
    Montalvo-Castro RE; Salinas-Jazmín N
    Gac Med Mex; 2022; 158(3):141-149. PubMed ID: 35894744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of membrane-bound complement regulatory proteins in prostate cancer.
    Loberg RD; Wojno KJ; Day LL; Pienta KJ
    Urology; 2005 Dec; 66(6):1321-6. PubMed ID: 16360477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury.
    Song WC
    Curr Dir Autoimmun; 2004; 7():181-99. PubMed ID: 14719381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.
    Cui W; Zhao Y; Shan C; Kong G; Hu N; Zhang Y; Zhang S; Zhang W; Zhang Y; Zhang X; Ye L
    FEBS Lett; 2012 Mar; 586(6):766-71. PubMed ID: 22293503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.
    Das N; Biswas B; Khera R
    Adv Exp Med Biol; 2013; 735():55-81. PubMed ID: 23402019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.